Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$16.36
At close: May 15 EDT
$16.30
-0.06-0.37%
Pre-Market: 4:53 PM EDT
Comments
Loading...
Apellis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:APLS | Benzinga
Apellis Pharmaceuticals Inc has a consensus price target of $43.7 based on the ratings of 21 analysts. The high is $106 issued by Raymond James on January 11, 2024. The low is $18 issued by RBC Capital on May 8, 2025. The 3 most-recent analyst ratings were released by Mizuho, Raymond James, and B of A Securities on May 14, 2025, May 9, 2025, and May 9, 2025, respectively. With an average price target of $31.67 between Mizuho, Raymond James, and B of A Securities, there's an implied 94.27% upside for Apellis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
Raymond James
B of A Securities
RBC Capital
Scotiabank
1calculated from analyst ratings
Analyst Ratings for Apellis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2025 | Buy Now | 22.7% | Mizuho | Graig Suvannavejh51% | $30 → $20 | Maintains | Neutral | Get Alert |
| 05/09/2025 | Buy Now | 219.02% | Raymond James | Ryan Deschner74% | $75 → $52 | Downgrade | Strong Buy → Outperform | Get Alert |
| 05/09/2025 | Buy Now | 41.1% | B of A Securities | Tazeen Ahmad53% | $41 → $23 | Downgrade | Buy → Neutral | Get Alert |
| 05/08/2025 | Buy Now | 10.43% | RBC Capital | Luca Issi40% | $21 → $18 | Maintains | Sector Perform | Get Alert |
| 05/08/2025 | Buy Now | 22.7% | Scotiabank | Greg Harrison47% | $28 → $20 | Maintains | Sector Perform | Get Alert |
| 05/08/2025 | Buy Now | 59.51% | Wells Fargo | Derek Archila57% | $30 → $26 | Maintains | Equal-Weight | Get Alert |
| 05/08/2025 | Buy Now | 188.34% | Baird | Colleen Kusy34% | $55 → $47 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 77.91% | Needham | Joseph Stringer50% | $40 → $29 | Maintains | Buy | Get Alert |
| 04/29/2025 | Buy Now | 169.94% | Cantor Fitzgerald | Eliana Merle43% | → $44 | Initiates | → Overweight | Get Alert |
| 04/21/2025 | Buy Now | 28.83% | RBC Capital | Luca Issi40% | $24 → $21 | Maintains | Sector Perform | Get Alert |
| 04/02/2025 | Buy Now | 90.18% | Scotiabank | Greg Harrison47% | $30 → $31 | Maintains | Sector Perform | Get Alert |
| 03/04/2025 | Buy Now | 231.29% | JP Morgan | Anupam Rama57% | $50 → $54 | Maintains | Overweight | Get Alert |
| 03/03/2025 | Buy Now | 53.37% | RBC Capital | Luca Issi40% | $26 → $25 | Maintains | Sector Perform | Get Alert |
| 03/03/2025 | Buy Now | 96.32% | Goldman Sachs | Salveen Richter52% | $36 → $32 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 77.91% | Wedbush | Laura Chico46% | $30 → $29 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | 249.69% | HC Wainwright & Co. | Douglas Tsao50% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 02/13/2025 | Buy Now | 249.69% | HC Wainwright & Co. | Douglas Tsao50% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | 59.51% | RBC Capital | Luca Issi40% | $26 → $26 | Maintains | Sector Perform | Get Alert |
| 01/21/2025 | Buy Now | 59.51% | RBC Capital | Luca Issi40% | $26 → $26 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 01/14/2025 | Buy Now | 249.69% | HC Wainwright & Co. | Douglas Tsao50% | $57 → $57 | Reiterates | Buy → Buy | Get Alert |
| 12/17/2024 | Buy Now | 120.86% | Goldman Sachs | Salveen Richter52% | → $36 | Downgrade | Buy → Neutral | Get Alert |
| 11/21/2024 | Buy Now | 90.18% | Morgan Stanley | Judah Frommer65% | → $31 | Initiates | → Equal-Weight | Get Alert |
| 11/07/2024 | Buy Now | 237.42% | Baird | Colleen Kusy34% | $92 → $55 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 212.88% | Citigroup | Yigal Nochomovitz53% | $63 → $51 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 120.86% | Goldman Sachs | Salveen Richter52% | $71 → $36 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 47.24% | RBC Capital | Luca Issi40% | $25 → $24 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 84.05% | Scotiabank | Greg Harrison47% | $35 → $30 | Maintains | Sector Perform | Get Alert |
| 11/06/2024 | Buy Now | 84.05% | Wells Fargo | Derek Archila57% | $43 → $30 | Maintains | Equal-Weight | Get Alert |
| 11/06/2024 | Buy Now | 145.4% | Oppenheimer | Justin Kim36% | $65 → $40 | Maintains | Outperform | Get Alert |
| 11/06/2024 | Buy Now | 96.32% | Piper Sandler | Biren Amin39% | $40 → $32 | Maintains | Neutral | Get Alert |
| 11/06/2024 | Buy Now | 249.69% | HC Wainwright & Co. | Douglas Tsao50% | $83 → $57 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 188.34% | B of A Securities | Tazeen Ahmad53% | $61 → $47 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | 268.1% | Needham | Joseph Stringer50% | $85 → $60 | Maintains | Buy | Get Alert |
| 11/04/2024 | Buy Now | 53.37% | RBC Capital | Luca Issi40% | $25 → $25 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 10/24/2024 | Buy Now | 133.13% | Mizuho | Graig Suvannavejh51% | $39 → $38 | Maintains | Neutral | Get Alert |
| 10/16/2024 | Buy Now | 114.72% | Scotiabank | Greg Harrison47% | → $35 | Initiates | → Sector Perform | Get Alert |
| 10/16/2024 | Buy Now | — | William Blair | Lachlan Brown33% | — | Initiates | → Outperform | Get Alert |
| 09/24/2024 | Buy Now | 163.8% | Wells Fargo | Derek Archila57% | $47 → $43 | Maintains | Equal-Weight | Get Alert |
| 09/23/2024 | Buy Now | 464.42% | Baird | Colleen Kusy34% | $96 → $92 | Maintains | Outperform | Get Alert |
| 09/20/2024 | Buy Now | 139.26% | Mizuho | Graig Suvannavejh51% | $42 → $39 | Maintains | Neutral | Get Alert |
| 09/20/2024 | Buy Now | 421.47% | Needham | Joseph Stringer50% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2024 | Buy Now | 249.69% | JP Morgan | Anupam Rama57% | $64 → $57 | Maintains | Overweight | Get Alert |
| 08/13/2024 | Buy Now | 292.64% | JP Morgan | Anupam Rama57% | $72 → $64 | Maintains | Overweight | Get Alert |
| 08/09/2024 | Buy Now | 409.2% | UBS | Eliana Merle43% | $85 → $83 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 151.53% | Wedbush | Laura Chico46% | $38 → $41 | Maintains | Neutral | Get Alert |
| 08/09/2024 | Buy Now | 353.99% | Goldman Sachs | Salveen Richter52% | $66 → $74 | Maintains | Buy | Get Alert |
| 08/09/2024 | Buy Now | 488.96% | Baird | Colleen Kusy34% | $86 → $96 | Maintains | Outperform | Get Alert |
| 08/09/2024 | Buy Now | 421.47% | Needham | Joseph Stringer50% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 409.2% | HC Wainwright & Co. | Douglas Tsao50% | $92 → $83 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 304.91% | Goldman Sachs | Salveen Richter52% | $77 → $66 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 421.47% | Needham | Joseph Stringer50% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2024 | Buy Now | 390.8% | Jefferies | Akash Tewari41% | $80 → $80 | Maintains | Buy | Get Alert |
| 07/26/2024 | Buy Now | 427.61% | Baird | Colleen Kusy34% | $100 → $86 | Maintains | Outperform | Get Alert |
| 07/23/2024 | Buy Now | 513.5% | Baird | Colleen Kusy34% | $100 → $100 | Maintains | Outperform | Get Alert |
| 07/17/2024 | Buy Now | 372.39% | Goldman Sachs | Salveen Richter52% | $90 → $77 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 513.5% | Baird | Colleen Kusy34% | $100 → $100 | Maintains | Outperform | Get Alert |
| 05/31/2024 | Buy Now | 182.21% | Piper Sandler | Biren Amin39% | → $46 | Initiates | → Neutral | Get Alert |
| 05/28/2024 | Buy Now | 464.42% | HC Wainwright & Co. | Douglas Tsao50% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2024 | Buy Now | 194.48% | Wells Fargo | Derek Archila57% | $57 → $48 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 421.47% | Needham | Joseph Stringer50% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 268.1% | Citigroup | Yigal Nochomovitz53% | $67 → $60 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | 464.42% | HC Wainwright & Co. | Douglas Tsao50% | → $92 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 421.47% | UBS | Eliana Merle43% | $89 → $85 | Maintains | Buy | Get Alert |
| 04/29/2024 | Buy Now | 219.02% | Mizuho | Graig Suvannavejh51% | $60 → $52 | Maintains | Neutral | Get Alert |
| 04/26/2024 | Buy Now | 464.42% | HC Wainwright & Co. | Douglas Tsao50% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 421.47% | Needham | Joseph Stringer50% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 04/17/2024 | Buy Now | 249.69% | Wedbush | Laura Chico46% | $67 → $57 | Maintains | Neutral | Get Alert |
| 04/15/2024 | Buy Now | 464.42% | HC Wainwright & Co. | Douglas Tsao50% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 421.47% | Needham | Joseph Stringer50% | $85 → $85 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 268.1% | Mizuho | Graig Suvannavejh51% | $60 → $60 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | 384.66% | JP Morgan | Anupam Rama57% | $78 → $79 | Maintains | Overweight | Get Alert |
| 03/04/2024 | Buy Now | 446.01% | UBS | Eliana Merle43% | $87 → $89 | Maintains | Buy | Get Alert |
| 02/28/2024 | Buy Now | 464.42% | HC Wainwright & Co. | Douglas Tsao50% | $92 → $92 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 311.04% | Wedbush | Laura Chico46% | $60 → $67 | Maintains | Neutral | Get Alert |
| 02/16/2024 | Buy Now | 268.1% | Mizuho | Graig Suvannavejh51% | $49 → $60 | Maintains | Neutral | Get Alert |
| 02/06/2024 | Buy Now | 396.93% | Baird | Colleen Kusy34% | → $81 | Reiterates | Outperform → Outperform | Get Alert |
| 02/05/2024 | Buy Now | 390.8% | Jefferies | Akash Tewari41% | $68 → $80 | Upgrade | Hold → Buy | Get Alert |
| 01/30/2024 | Buy Now | 384.66% | Oppenheimer | Justin Kim36% | $75 → $79 | Maintains | Outperform | Get Alert |
| 01/24/2024 | Buy Now | 360.12% | Needham | Joseph Stringer50% | $70 → $75 | Maintains | Buy | Get Alert |
| 01/17/2024 | Buy Now | 396.93% | Baird | Colleen Kusy34% | $71 → $81 | Maintains | Outperform | Get Alert |
| 01/17/2024 | Buy Now | 464.42% | HC Wainwright & Co. | Douglas Tsao50% | $82 → $92 | Maintains | Buy | Get Alert |
| 01/12/2024 | Buy Now | 268.1% | Wedbush | Laura Chico46% | $39 → $60 | Maintains | Neutral | Get Alert |
| 01/11/2024 | Buy Now | 550.31% | Raymond James | Steven Seedhouse58% | $67 → $106 | Maintains | Strong Buy | Get Alert |
| 01/09/2024 | Buy Now | 452.15% | Goldman Sachs | Salveen Richter52% | $65 → $90 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 311.04% | Citigroup | Yigal Nochomovitz53% | $70 → $67 | Maintains | Buy | Get Alert |
| 12/15/2023 | Buy Now | 360.12% | Oppenheimer | Justin Kim36% | $88 → $75 | Maintains | Outperform | Get Alert |
| 12/15/2023 | Buy Now | 311.04% | Raymond James | Steven Seedhouse58% | $93 → $67 | Maintains | Strong Buy | Get Alert |
| 12/14/2023 | Buy Now | 243.56% | Needham | Joseph Stringer50% | $63 → $56 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 231.29% | Wells Fargo | Derek Archila57% | $67 → $54 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/05/2023 | Buy Now | 421.47% | B of A Securities | Tazeen Ahmad53% | $52 → $85 | Upgrade | Neutral → Buy | Get Alert |
| 11/09/2023 | Buy Now | 353.99% | Goldman Sachs | Salveen Richter52% | → $74 | Initiates | → Buy | Get Alert |
| 11/02/2023 | Buy Now | 157.67% | Mizuho | Graig Suvannavejh51% | → $42 | Initiates | → Neutral | Get Alert |
| 11/02/2023 | Buy Now | 470.55% | Raymond James | Steven Seedhouse58% | $92 → $93 | Maintains | Strong Buy | Get Alert |
| 11/01/2023 | Buy Now | 286.5% | Needham | Joseph Stringer50% | $60 → $63 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | 182.21% | B of A Securities | Tazeen Ahmad53% | $44 → $46 | Maintains | Neutral | Get Alert |
| 10/06/2023 | Buy Now | 329.45% | Citigroup | Yigal Nochomovitz53% | $54 → $70 | Maintains | Buy | Get Alert |
| 10/06/2023 | Buy Now | 396.93% | JP Morgan | Anupam Rama57% | $60 → $81 | Upgrade | Neutral → Overweight | Get Alert |
| 10/06/2023 | Buy Now | 464.42% | Raymond James | Steven Seedhouse58% | $89 → $92 | Maintains | Strong Buy | Get Alert |
| 09/26/2023 | Buy Now | 403.07% | HC Wainwright & Co. | Douglas Tsao50% | → $82 | Reiterates | Buy → Buy | Get Alert |
| 09/20/2023 | Buy Now | 403.07% | HC Wainwright & Co. | Douglas Tsao50% | → $82 | Reiterates | Buy → Buy | Get Alert |
FAQ
What is the target price for Apellis Pharmaceuticals (APLS) stock?
The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by Mizuho on May 14, 2025. The analyst firm set a price target for $20.00 expecting APLS to rise to within 12 months (a possible 22.70% upside). 59 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Apellis Pharmaceuticals (APLS)?
The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by Mizuho, and Apellis Pharmaceuticals maintained their neutral rating.
When was the last upgrade for Apellis Pharmaceuticals (APLS)?
The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.
When was the last downgrade for Apellis Pharmaceuticals (APLS)?
The last downgrade for Apellis Pharmaceuticals Inc happened on May 9, 2025 when Raymond James changed their price target from $75 to $52 for Apellis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Apellis Pharmaceuticals (APLS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on May 14, 2025 so you should expect the next rating to be made available sometime around May 14, 2026.
Is the Analyst Rating Apellis Pharmaceuticals (APLS) correct?
While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a maintained with a price target of $30.00 to $20.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $16.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
